PRX002

DRUG2 trials

Sponsors

Prothena Biosciences Limited

Conditions

Parkinson's Disease

Phase 1

Single Ascending Dose Study of PRX002 in Healthy Subjects

CompletedNCT02095171

Prothena Biosciences LimitedParkinson's Disease

Start: 2014-03-31Target: 40Updated: 2015-02-10

Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

CompletedNCT02157714

Prothena Biosciences LimitedParkinson's Disease

Start: 2014-06-30Target: 64Updated: 2016-10-21

Related Papers

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data

Frontiers in Neurology2021-10-0177 citations

Antibody-based immunotherapies for Parkinsonian syndromes

Neural Regeneration Research2019-01-014 citations

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

JAMA Neurology2018-06-18283 citations